High-Titer rAAV Production In Bioreactors Using ELEVECTA™ Stable Producer Cell Lines

By J. Coronel, A. Al-Dali, A. Patil, K. Srinivasan, T. Braß, K. Hein, and S. Wissing

Recombinant adeno-associated virus (rAAV) is commonly used as a viral gene therapy vector. However, delivering the necessary quantities of vectors and ensuring their quality remains a challenge. The ELEVECTA™ AAV production platform, based on mammalian suspension cells, addresses this challenge with stable integration of all essential components for AAV production: adenovirus helper functions, AAV replicase, AAV capsid, and the gene of interest (GOI; transgene).

Here, we outline the upstream process development and optimization for an AAV8-GFP proof-of-concept (PoC) producer single cell clone (SCC) in both batch and perfusion modes.